Intensity TherapeuticsINTS +5.75%28 3-Year ROIIC % is 171.73 as of Dec. 2025, which is 166% above its 10-year median of 64.57. GuruFocus rates INTS with a GF Score™ of 28/100. The stock has 1 warning sign investors should review. Among 1,319 Biotechnology companies, Intensity Therapeutics ranks better than 82.79% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Intensity Therapeutics's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was 171.73%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Intensity Therapeutics's 3-Year ROIIC % or its related term are showing as below:
INTS's 3-Year ROIIC % is ranked better than 82.79% of 1319
companies
in the Biotechnology industry
Industry Median: -4.44
vs INTS: 171.73
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Intensity Therapeutics 3-Year ROIIC % Related Terms
Intensity Therapeutics 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Intensity Therapeutics's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
INTS vs KPRX, PHIO, PBM: 3-Year ROIIC % Comparison
For the Biotechnology subindustry, Intensity Therapeutics's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Intensity Therapeutics 3-Year ROIIC % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Intensity Therapeutics's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Intensity Therapeutics's 3-Year ROIIC % falls into.
Intensity Therapeutics's 3-Year ROIIC % for the quarter that ended in Dec. 2025 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( -11.972 (Dec. 2025) - -7.55 (Dec. 2022) )
/
( 2.223 (Dec. 2025) - 4.798 (Dec. 2022) )
=
-4.422
/
-2.575
=
171.73%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Intensity Therapeutics (INTS) has a 3-Year ROIIC % of 171.73 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Intensity Therapeutics and its competitors. This is 166% above median its historical median of 64.57. According to the industry distribution chart, Intensity Therapeutics ranks #227 out of 1319 companies in the Biotechnology industry, placing it in the top 17.2%.
Is Intensity Therapeutics' 3-Year ROIIC % too high?
Intensity Therapeutics' current 3-Year ROIIC % of 171.73 is 166% above median its 10-year median of 64.57. Based on the distribution chart, Intensity Therapeutics ranks #227 out of 1319 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Intensity Therapeutics has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Intensity Therapeutics' 3-Year ROIIC % compare to KPRX and PHIO?
According to the Biotechnology industry distribution chart, Intensity Therapeutics ranks #227 out of 1319 companies for 3-Year ROIIC %. This places Intensity Therapeutics in the top 17% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Biotechnology company?
A good 3-Year ROIIC % depends on the Biotechnology industry context. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Intensity Therapeutics and its competitors. Intensity Therapeutics's current 3-Year ROIIC % is 171.73, which is 166% above median its own 10-year median of 64.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Intensity Therapeutics stock overvalued right now?
Intensity Therapeutics (INTS) has a current 3-Year ROIIC % of 171.73. The current 3-Year ROIIC % is 171.73, which is 166% above median its 10-year median of 64.57. Intensity Therapeutics' overall GF Score™ is 28/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Intensity Therapeutics (INTS), the current 3-Year ROIIC % is 171.73 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Intensity Therapeutics Inc is a late-stage clinical biotechnology company passionately committed to applying scientific leadership in the field of localized cancer reduction to anti-cancer immune activation. Its new approach involves the direct injection into tumors of a product created from DfuseRxSM discovery platform. Its platform creates patented anti-cancer product candidates comprising active anti-cancer agents and amphiphilic molecules. Its product candidate, INT230-6 comprised of three components: cisplatin, a anti-cancer cytotoxic agent, vinblastine sulfate, also a anti-cancer cytotoxic agent, and an amphiphilic molecule which enables the two cytotoxic agents to disperse through a tumor and diffuse into cancer cells following a direct intratumoral injection.
28GF Score
Get the complete analysis for INTS
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
INTS has been successfully added to your 
